Participated · Seed · Nov 2021

Nebula Biocides, founded in 2019 as a spin‑off from the Leibniz Institute for Plasma Science and Technology (INP), develops the Sporosan® disinfection process based on peroxynitrite acid. The product uses two starting components that react briefly to produce a highly disinfecting effect that the company says is effective against bacteria, viruses and resistant bacterial spores. Nebula positions Sporosan® as both environmentally friendly and gentle in use, with particular potential to prevent infections from Clostridioides difficile. The team of five is pursuing two parallel regulatory and commercialization paths: approval of Sporosan® as a biocidal product and development of sporicidal reprocessing solutions for medical devices. With a strategic industrial partner already engaged, the company expects a medical‑device market launch in 2024 and aims for biocidal product availability for hand and surface disinfection by around 2028. The recent seed financing is being used to fund the studies required for regulatory compliance and broader commercialization.

Participated · Series A · Mar 2021

Founded in 2016, Hepster operates an API-driven ecosystem that allows companies across industries to embed needs-based, individual insurance policies directly into their own offerings. Its portfolio spans mobility, electronics, equipment, travel, pet, and accident insurance, giving partners a wide range of coverages to bundle with their products or services. To date the company has secured more than 2,500 partners and serves over 250,000 customers with a catalogue of more than 500 customised insurance products. Headquartered in Rostock, Germany, Hepster currently operates in Germany and Austria and expanded into France in spring 2022. The platform’s flexibility and breadth have positioned it as a key provider in the rapidly growing embedded insurance sector. With the fresh capital, management plans to accelerate geographic expansion, maintain sustainable growth, and chart a clear path to profitability. These efforts aim to cement Hepster’s foothold in existing markets while opening new revenue streams in additional European territories.

Participated · Equity · Nov 2018

AIM3D, founded in 2017 as a spin-off of the University of Rostock, develops 3D multi-material printers that use standard injection-molding granules. Its systems can print products made of metals, ceramics, plastics and reinforced plastics. The company plans to use recently raised funds to expand operations and to launch series production of the ExAM 510 industrial printer. Backers in the round included The HZG Group, High‑Tech Gründerfonds (HTGF) and other early-stage investors. AIM3D is based in Rostock, Germany and currently employs 17 people. The amount raised was not disclosed. AIM3D GmbH, a spin-off of the University of Rostock, builds 3D metal printers and has developed a new process for producing metal parts using 3D printing. The technology enables manufacturing of components from materials typical in automotive series production. The company is led by Managing Director Vincent Morrison. AIM3D's stated goal is the industrialization of 3D printing through use of standard injection molding granules, CNC technology and automation interfaces. The firm planned to launch its ExAM 255 machine in spring 2019. To support these efforts, AIM3D raised funding from external backers.